News

Bavarian Nordic A/S announced that the European Commission (EC) has extended the marketing authorization for the Company’s smallpox vaccine, IMVANEX to include protection from monkeypox…
Read More...

Sandoz announced that the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA) for a proposed first-of-a-kind biosimilar natalizumab, developed by…
Read More...

Today, Ginkgo Bioworks — the leading horizontal platform for cell programming — and the biotechnology company Zymergen announced they have entered into a definitive agreement under…
Read More...

NewAmsterdam Pharma Holding B.V. a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, and Frazier…
Read More...

Sangamo Therapeutics, Inc. announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a wholly-owned autologous Chimeric Antigen…
Read More...

Gilead Sciences, Inc. announced its upcoming contributions to the 24th International AIDS Conference (AIDS 2022). AIDS 2022 will be a hybrid conference, taking place in person in…
Read More...

As many Korean pharmaceutical manufacturers are currently attempting to develop new drugs for idiopathic pulmonary fibrosis, Daewoong Pharmaceutical's new medication DWN12088 has been…
Read More...

February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (“LiberoThera”) to co-develop fully human…
Read More...

Artizan Biosciences, Inc. (“Artizan”), a biotechnology company creating gut exclusive microbial metalloprotease inhibitors (GEMMi), a new class of transformative precision therapeutics…
Read More...

Valneva SE announces that the European Commission (EC) has approved an amendment to the Advance Purchase Agreement (APA) it signed in November 2021 for Valneva’s inactivated whole-virus…
Read More...

CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy protein expression, announced the closing of a $100 million Series B round to advance the…
Read More...

AstraZeneca is supplying Switzerland with approximately 1,200 doses of tixagevimab and cilgavimab, a long-acting combination antibody therapy, for the treatment of COVID-19. The Swiss…
Read More...

Karyopharm Therapeutics Inc. announced new regulatory designations for eltanexor, a novel oral, Selective Inhibitor of Nuclear Export (SINE) investigational compound being studied for…
Read More...

ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address…
Read More...

Sorrento Therapeutics, Inc. announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic…
Read More...

Avista Therapeutics, which recently launched as a spinout of leading health system UPMC, aims to develop innovative gene therapies for rare ophthalmic conditions. The new company…
Read More...

Gilead Sciences and the European Commission signed a new joint procurement agreement (JPA) that will ensure continued rapid and equitable access to Veklury (remdesivir) for…
Read More...

Nabriva Therapeutics plc announced that it has entered into an exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the…
Read More...

Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked patients announced the U.S. Food and…
Read More...

AbbVie announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who…
Read More...